Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CrkL Antibodies:
anti-Rat (Rattus) CrkL Antibodies:
anti-Mouse (Murine) CrkL Antibodies:
Go to our pre-filtered search.
Human Monoclonal CrkL Primary Antibody for WB - ABIN967605
Arai, Nosaka, Kohsaka, Miyasaka, Miura: CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G. in Blood 1999
Show all 3 references for ABIN967605
Human Polyclonal CrkL Primary Antibody for IHC, ELISA - ABIN184660
Singer, Hudelist, Lamm, Mueller, Handl, Kubista, Czerwenka: Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. in Oncology reports 2006
Human Monoclonal CrkL Primary Antibody for FACS, ELISA - ABIN969064
Seo, Suenaga, Hatakeyama, Taiji, Imamoto: Structural and functional basis of a role for CRKL in a fibroblast growth factor 8-induced feed-forward loop. in Molecular and cellular biology 2009
The adaptor proteins Crk (show CRK Antibodies) and Crk (show CRK Antibodies)-like (Crkl), with which Dock proteins are known to interact physically, are also required for myoblast fusion.
CrkL mediates CCL20 (show CCL20 Antibodies)/CCR6 (show CCR6 Antibodies)-induced epithelial-to-mesenchymal transition via Akt (show AKT1 Antibodies) pathway, instead of Erk1/2 (show MAPK1/3 Antibodies) pathway in development of gastric cancer
CrkL regulates CCL19 (show CCL19 Antibodies) and CCR7 (show CCR7 Antibodies)-induced epithelial-to-mesenchymal transition via ERK (show EPHB2 Antibodies) signaling pathway in epithelial ovarian carcinoma patients.
these results suggest that CrkL plays a regulatory role in the SDF-1 (show CXCL12 Antibodies)-induced Erk1/2 (show MAPK1/3 Antibodies) and PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) pathways and further managed the invasion and migration of breast cancer cells
The authors show that this potentiation involves reorganization of the natural CrkL-p85beta complex into a novel trimeric complex where influenza A virus NS1 serves as a bridging factor.
Our results demonstrate that the p53 (show TP53 Antibodies) target miR (show MLXIP Antibodies)-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene (show RAB1A Antibodies)
results suggested that overexpression of CRKL promoted cell invasion through upregulation of MMP9 (show MMP9 Antibodies) expression and activation of ERK (show EPHB2 Antibodies) pathway
CRKL has the potential to be used as a biomarker for the diagnosis, treatment and prognosis of certain tumors
We identified ZEB1 (show ZEB1 Antibodies) and CRKL as potential targets of miR (show MLXIP Antibodies)-429 by analyzing combined results from in silico search and global expression array of the same RNA samples. Immunoblot assay confirmed that miR (show MLXIP Antibodies)-429 reduced their expression at protein level.
These results indicate that CRKL gene amplification is rare in acquisition of resistance to EGFR (show EGFR Antibodies)-TKIs in lung cancer patients with EGFR (show EGFR Antibodies) mutations.
CrkL knockdown markedly suppressed the phosphorylated ERK (show EPHB2 Antibodies) (p-ERK (show EPHB2 Antibodies)) as well as the phosphorylated AKT (p-AKT (show AKT1 Antibodies)) (p < 0.001) compared with control or TGF-b1 alone.
both Crk and CrkL are required for the acquisition of cellular transformation by v-fos, whereas Crk plays a more prominent role than CrkL in v-ras-induced transformation.
The study screened CrkL binding proteins using RNA interference (RNAi) and identified Sorbs1 (show SORBS1 Antibodies) and Sorbs2 (show Sorbs2 Antibodies) as two proteins that are enriched at AChR clusters and are required for the formation of AChR aggregation in vitro.
CRKL plays an important role in hepatocarcinoma cell proliferation, invasion and migration as well hepatocarcinoma malignancy and metastasis.
CRKL is shown to act as a potential suppressor and to provide new insight for both the malignant behaviors of hepatocarcinoma cells and lymphatic metastasis mechanism of hepatocarcinoma.
Sprouty2 acts as an inhibitor of CrkL-Rap1 signaling.
Differential migration of CRK (show CRK Antibodies)/CRKL-deficient T cells resulted in efficient graft-versus-leukemia responses with minimal graft-versus-host disease in mice.
Crk1 (show MAPK14 Antibodies)/2 and CrkL are physically linked, functionally complement each other during podocyte foot process spreading, and together are required for developing typical foot process architecture.
Results suggest that Crk (show CRK Antibodies) and CrkL have critical roles in cell structure and motility by maintaining cytoskeletal integrity.
The molecular signaling set off by ERalpha (show ESR1 Antibodies) and CrkL association may have a central role in pregnancy and cancer.
Reelin-induced Dab1 tyrosine phosphorylation may generate a multifaceted signaling scaffold containing a rich array of Crk/CrkL-SH3 binding effectors
This gene encodes a protein kinase containing SH2 and SH3 (src homology) domains which has been shown to activate the RAS and JUN kinase signaling pathways and transform fibroblasts in a RAS-dependent fashion. It is a substrate of the BCR-ABL tyrosine kinase, plays a role in fibroblast transformation by BCR-ABL, and may be oncogenic.
v-crk sarcoma virus CT10 oncogene homolog (avian)-like
, crk-like protein
, v-crk sarcoma virus CT10 oncogene homolog-like
, v-crk avian sarcoma virus CT10 oncogene homolog-like